Lucent Drugs Profile
Key Indicators
- Authorised Capital ₹ 9.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 6.28 Cr
as on 24-10-2024
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 35.44 Cr
as on 24-10-2024
- Revenue -8.35%
(FY 2023)
- Profit -29.85%
(FY 2023)
- Ebitda -18.85%
(FY 2023)
- Net Worth 52.01%
(FY 2023)
- Total Assets 49.29%
(FY 2023)
About Lucent Drugs
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.00 Cr and a paid-up capital of Rs 6.28 Cr.
The company currently has active open charges totaling ₹35.44 Cr.
Sreenivasulu Devarasetty and Mahaveer Jain serve as directors at the Company.
- CIN/LLPIN
U24100TG2017PTC118662
- Company No.
118662
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Aug 2017
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Lucent Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sreenivasulu Devarasetty  | Director | 02-Aug-2017 | Current |
| Mahaveer Jain | Director | 14-Jun-2022 | Current |
Financial Performance of Lucent Drugs.
Lucent Drugs Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.35% decrease. The company also saw a substantial fall in profitability, with a 29.85% decrease in profit. The company's net worth Soared by an impressive increase of 52.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lucent Drugs?
In 2023, Lucent Drugs had a promoter holding of 73.63% and a public holding of 26.37%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Inter Labs (India) Private LimitedActive 19 years 3 monthsSreenivasulu Devarasetty is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Standard Chartered Bank Creation Date: 26 Aug 2024 | ₹18.89 Cr | Open |
Hdfc Bank Limited Creation Date: 02 Dec 2022 | ₹2.33 M | Open |
Hdfc Bank Limited Creation Date: 21 Oct 2022 | ₹2.21 M | Open |
How Many Employees Work at Lucent Drugs?
Lucent Drugs has a workforce of 63 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lucent Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lucent Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
